FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012824126> ?p ?o ?g. }

• W2012824126 endingPage "e105442" @default.
• W2012824126 startingPage "e105442" @default.
• W2012824126 abstract "Objectives Infection with co-pathogens is one of the postulated factors contributing to persistent inflammation and non-AIDS events in virologically-suppressed HIV-infected patients. We aimed to investigate the relationship of human herpesvirus-8 (HHV-8), a vasculotropic virus implicated in the pathogenesis of Kaposi's sarcoma, with inflammation and subclinical atherosclerosis in HIV-infected patients. Methods Prospective study including virologically suppressed HIV-infected patients. Several blood biomarkers (highly-sensitive C-reactive protein [hsCRP], tumour necrosis factor-α, interleukin-6, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, intercellular cell adhesion molecule-1, malondialdehyde, plasminogen activator inhibitor [PAI-1], D-dimer, sCD14, sCD163, CD4/CD38/HLA-DR, and CD8/CD38/HLA-DR), serological tests for HHV-8 and the majority of herpesviruses, carotid intima-media thickness, and endothelial function through flow-mediated dilatation of the brachial artery were measured. Results A total of 136 patients were included, 34.6% of them infected with HHV-8. HHV-8-infected patients were more frequently co-infected with herpes simplex virus type 2 (HSV-2) (P<0.001), and less frequently with hepatitis C virus (HCV) (P = 0.045), and tended to be older (P = 0.086). HHV-8-infected patients had higher levels of hsCRP (median [interquartile range], 3.63 [1.32–7.54] vs 2.08 [0.89–4.11] mg/L, P = 0.009), CD4/CD38/HLA-DR (7.67% [4.10–11.86]% vs 3.86% [2.51–7.42]%, P = 0.035) and CD8/CD38/HLA-DR (8.02% [4.98–14.09]% vs 5.02% [3.66–6.96]%, P = 0.018). After adjustment for the traditional cardiovascular risk factors, HCV and HSV-2 infection, the associations remained significant: adjusted difference between HHV-8 positive and negative patients (95% confidence interval) for hsCRP, 74.19% (16.65–160.13)%; for CD4/CD38/HLA-DR, 89.65% (14.34–214.87)%; and for CD8/CD38/HLA-DR, 58.41% (12.30–123.22)%. Flow-mediated dilatation and total carotid intima-media thickness were not different according to HHV-8 serostatus. Conclusion In virologically suppressed HIV-infected patients, coinfection with HHV-8 is associated with increased inflammation and immune activation. This might contribute to increase the risk of non-AIDS events, including accelerated atherosclerotic disease." @default.
• W2012824126 created "2016-06-24" @default.
• W2012824126 creator A5020067318 @default.
• W2012824126 creator A5026934961 @default.
• W2012824126 creator A5032071061 @default.
• W2012824126 creator A5040594505 @default.
• W2012824126 creator A5060315768 @default.
• W2012824126 creator A5062887718 @default.
• W2012824126 creator A5079700165 @default.
• W2012824126 date "2014-08-18" @default.
• W2012824126 modified "2023-10-17" @default.
• W2012824126 title "Coinfection with Human Herpesvirus 8 Is Associated with Persistent Inflammation and Immune Activation in Virologically Suppressed HIV-Infected Patients" @default.
• W2012824126 cites W1970238107 @default.
• W2012824126 cites W1979542633 @default.
• W2012824126 cites W1990419414 @default.
• W2012824126 cites W1990922925 @default.
• W2012824126 cites W1993957477 @default.
• W2012824126 cites W1997528586 @default.
• W2012824126 cites W2011490846 @default.
• W2012824126 cites W2013410243 @default.
• W2012824126 cites W2020900103 @default.
• W2012824126 cites W2023169697 @default.
• W2012824126 cites W2026616659 @default.
• W2012824126 cites W2028981988 @default.
• W2012824126 cites W2029148240 @default.
• W2012824126 cites W2030347968 @default.
• W2012824126 cites W2040128163 @default.
• W2012824126 cites W2044588509 @default.
• W2012824126 cites W2058610272 @default.
• W2012824126 cites W2071991610 @default.
• W2012824126 cites W2096380205 @default.
• W2012824126 cites W2105804574 @default.
• W2012824126 cites W2110559078 @default.
• W2012824126 cites W2127517680 @default.
• W2012824126 cites W2133064188 @default.
• W2012824126 cites W2140437973 @default.
• W2012824126 cites W2148327106 @default.
• W2012824126 cites W2163935667 @default.
• W2012824126 cites W2172006543 @default.
• W2012824126 doi "https://doi.org/10.1371/journal.pone.0105442" @default.
• W2012824126 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4136871" @default.
• W2012824126 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25133669" @default.
• W2012824126 hasPublicationYear "2014" @default.
• W2012824126 type Work @default.
• W2012824126 sameAs 2012824126 @default.
• W2012824126 citedByCount "21" @default.
• W2012824126 countsByYear W20128241262015 @default.
• W2012824126 countsByYear W20128241262016 @default.
• W2012824126 countsByYear W20128241262017 @default.
• W2012824126 countsByYear W20128241262018 @default.
• W2012824126 countsByYear W20128241262019 @default.
• W2012824126 countsByYear W20128241262020 @default.
• W2012824126 countsByYear W20128241262021 @default.
• W2012824126 countsByYear W20128241262023 @default.
• W2012824126 crossrefType "journal-article" @default.
• W2012824126 hasAuthorship W2012824126A5020067318 @default.
• W2012824126 hasAuthorship W2012824126A5026934961 @default.
• W2012824126 hasAuthorship W2012824126A5032071061 @default.
• W2012824126 hasAuthorship W2012824126A5040594505 @default.
• W2012824126 hasAuthorship W2012824126A5060315768 @default.
• W2012824126 hasAuthorship W2012824126A5062887718 @default.
• W2012824126 hasAuthorship W2012824126A5079700165 @default.
• W2012824126 hasBestOaLocation W20128241261 @default.
• W2012824126 hasConcept C10205521 @default.
• W2012824126 hasConcept C126322002 @default.
• W2012824126 hasConcept C134659918 @default.
• W2012824126 hasConcept C159912055 @default.
• W2012824126 hasConcept C167672396 @default.
• W2012824126 hasConcept C178790620 @default.
• W2012824126 hasConcept C185592680 @default.
• W2012824126 hasConcept C203014093 @default.
• W2012824126 hasConcept C2522874641 @default.
• W2012824126 hasConcept C2776603314 @default.
• W2012824126 hasConcept C2776914184 @default.
• W2012824126 hasConcept C2777813720 @default.
• W2012824126 hasConcept C28328180 @default.
• W2012824126 hasConcept C54355233 @default.
• W2012824126 hasConcept C71924100 @default.
• W2012824126 hasConcept C84416704 @default.
• W2012824126 hasConcept C85789140 @default.
• W2012824126 hasConcept C86803240 @default.
• W2012824126 hasConcept C8891405 @default.
• W2012824126 hasConcept C90924648 @default.
• W2012824126 hasConceptScore W2012824126C10205521 @default.
• W2012824126 hasConceptScore W2012824126C126322002 @default.
• W2012824126 hasConceptScore W2012824126C134659918 @default.
• W2012824126 hasConceptScore W2012824126C159912055 @default.
• W2012824126 hasConceptScore W2012824126C167672396 @default.
• W2012824126 hasConceptScore W2012824126C178790620 @default.
• W2012824126 hasConceptScore W2012824126C185592680 @default.
• W2012824126 hasConceptScore W2012824126C203014093 @default.
• W2012824126 hasConceptScore W2012824126C2522874641 @default.
• W2012824126 hasConceptScore W2012824126C2776603314 @default.
• W2012824126 hasConceptScore W2012824126C2776914184 @default.
• W2012824126 hasConceptScore W2012824126C2777813720 @default.
• W2012824126 hasConceptScore W2012824126C28328180 @default.
• W2012824126 hasConceptScore W2012824126C54355233 @default.
• W2012824126 hasConceptScore W2012824126C71924100 @default.

• next